Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity

Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer

(2012) Andrew J. Weickhardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer

(2011) Yoshimichi Tanaka et al.   CANCER BIOLOGY & THERAPY

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

(2011) Y. Y. Janjigian et al.   CLINICAL CANCER RESEARCH

Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines

(2010) Marcel N.A. Bijman et al.   ANTI-CANCER DRUGS

Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer

(2010) S. K. Chambers et al.   CLINICAL CANCER RESEARCH

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

(2010) C. M. Annunziata et al.   CLINICAL CANCER RESEARCH

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)

(2010) Patricia Pautier et al.   GYNECOLOGIC ONCOLOGY

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment

(2010) Stephanie V. Blank et al.   GYNECOLOGIC ONCOLOGY

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

(2010) Julia Salih et al.   INTERNATIONAL JOURNAL OF CANCER

Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells

(2009) Thomas W. Grunt et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

(2009) Russell J. Schilder et al.   GYNECOLOGIC ONCOLOGY

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

(2008) P A Vasey et al.   BRITISH JOURNAL OF CANCER

Implications of EGFR inhibition in ovarian cancer cell proliferation

(2008) Shawna L. Bull Phelps et al.   GYNECOLOGIC ONCOLOGY

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

(2008) Jason Konner et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study

(2008) Angeles Alvarez Secord et al.   GYNECOLOGIC ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

Mycobacterium tuberculosis38-kDa Lipoprotein is Apoptogenic for Human Monocyte-derived Macrophages

(2008) A. Sanchez et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY